Education
About Us
Working with TipRanks
Follow Us
Mind Medicine Inc. (MNMD)
:MNMD
MNMD Stock Chart & Stats
$11.35
-$0.97(-11.96%)
At close: 4:00 PM EST
$11.35
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$4.70 - $14.43
Previous CloseN/A
Volume779.86K
Average Volume (3M)2.14M
Market Cap
$1.12B
Enterprise Value$843.91M
Total Cash (Recent Filing)$209.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Mar 05, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding98,509,280
10 Day Avg. Volume2,437,477
30 Day Avg. Volume2,143,223
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$28.25Price Target Upside148.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionMindMed secured $259M in financing, ensuring funding into 2028, which supports the completion of key programs.
Market OpportunityMindMed remains significantly undervalued as key Phase 3 data readouts for generalized anxiety disorder and major depressive disorder present great unmet need and significant market opportunity.
Pipeline AdvancementThe company is advancing its pivotal programs, with key data readouts for MM-120 in generalized anxiety disorder expected in 2026.
Bears Say
Mind Medicine News
MNMD FAQ
What was Mind Medicine Inc.’s price range in the past 12 months?
Mind Medicine Inc. lowest stock price was $4.70 and its highest was $14.43 in the past 12 months.
What is Mind Medicine Inc.’s market cap?
Mind Medicine Inc.’s market cap is $1.12B.
When is Mind Medicine Inc.’s upcoming earnings report date?
Mind Medicine Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 109 days.
How were Mind Medicine Inc.’s earnings last quarter?
Mind Medicine Inc. released its earnings results on Nov 06, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.279.
Is Mind Medicine Inc. overvalued?
According to Wall Street analysts Mind Medicine Inc.’s price is currently Undervalued.
Does Mind Medicine Inc. pay dividends?
Mind Medicine Inc. does not currently pay dividends.
What is Mind Medicine Inc.’s EPS estimate?
Mind Medicine Inc.’s EPS estimate is -0.51.
How many shares outstanding does Mind Medicine Inc. have?
Mind Medicine Inc. has 98,509,280 shares outstanding.
What happened to Mind Medicine Inc.’s price movement after its last earnings report?
Mind Medicine Inc. reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Mind Medicine Inc.?
Currently, no hedge funds are holding shares in MNMD
Mind Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.25 (148.90% Upside)
$28.25 (148.90% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.28%
12-Months-Change
Fundamentals
Return on Equity
-85.59%
Trailing 12-Months
Asset Growth
-25.91%
Trailing 12-Months
Company Description
Mind Medicine Inc.
Mind Medicine (MNMD), also known as MindMed, is a biotechnology company focused on developing psychedelic-inspired therapies for the treatment of mental health disorders. The company operates in the biopharmaceutical sector, primarily targeting conditions such as anxiety, depression, addiction, and ADHD through innovative drug development. MindMed's core products and services include research and development of novel psychedelic compounds, clinical trials, and collaborations with healthcare professionals to create effective mental health treatments.
MNMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a largely positive outlook for Mind Medicine (MindMed) Inc., with significant achievements in clinical trial progress, financial strengthening through capital raise, and promising advancements in their pipeline. However, increased expenses and net loss reflect some financial challenges.View all MNMD earnings summariesMNMD Stock 12 Month Forecast
Average Price Target
$28.25
▲(148.90% Upside)
Technical Analysis
Altimmune
―
Sana Biotechnology
―
Verve Therapeutics
―
ATAI Life Sciences
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
1.72% Insiders
4.15% Mutual Funds
0.64% Other Institutional Investors
87.24% Public Companies and Individual Investors